Engineered ketoreductase polypeptides
US-10006069-B2 · Jun 26, 2018 · US
US10752926B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10752926-B2 |
| Application number | US-201815982291-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 17, 2018 |
| Priority date | Aug 27, 2008 |
| Publication date | Aug 25, 2020 |
| Grant date | Aug 25, 2020 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present disclosure provides engineered ketoreductase enzymes having improved properties as compared to a naturally occurring wild-type ketoreductase enzyme. Also provided are polynucleotides encoding the engineered ketoreductase enzymes, host cells capable of expressing the engineered ketoreductase enzymes, and methods of using the engineered ketoreductase enzymes to synthesize a variety of chiral compounds. The engineered ketoreductase polypeptides are optimized for catalyzing the conversion of N-methyl-3-keto-3-(2-thienyl)-1-propanamine to (S)—N-methyl-3-hydroxy-3-(2-thienyl)-1-propanamine.
Opening claim text (preview).
What is claimed is: 1. A polynucleotide encoding a ketoreductase polypeptide capable of converting substrate N-methyl-3-keto-3-(2-thienyl)-1-propanamine to product (S)-N-methyl-3-hydroxy-3-(2-thienyl)-1-propanamine at a rate that is improved over a reference polypeptide having the amino acid sequence of SEQ ID NO:6, wherein the polypeptide has an amino acid sequence that is at least 90% identical to a reference sequence based on SEQ ID NO:2, comprising a substitution at position 46. 2. The polynucleotide encoding a ketoreductase polypeptide of claim 1 , comprising a further substitution at position 145. 3. The polynucleotide encoding a ketoreductase polypeptide of claim 1 , wherein position 190 is cysteine, proline, or a constrained amino acid; position 46 is arginine; position 60 is isoleucine; position 64 is valine; position 108 is histidine; position 152 is asparagine; position 153 is valine; position 157 is serine; position 198 is asparagine; position 199 is aspartic acid, valine, arginine, or phenylalanine; and/or position 245 is isoleucine. 4. The polynucleotide encoding a ketoreductase polypeptide of claim 1 , wherein the polypeptide is capable of converting the substrate to the product with a percent stereomeric excess of at least 95%. 5. The polynucleotide encoding a ketoreductase polypeptide of claim 1 , wherein the polypeptide is capable of converting the substrate to the product with a percent stereomeric excess of at least 99%. 6. The polynucleotide encoding a ketoreductase polypeptide of claim 1 , wherein the polypeptide is capable of converting the substrate to the product at a rate that is at least 10-15 times greater than the rate of conversion of the substrate to the product by the reference polypeptide of SEQ ID NO:6. 7. The polynucleotide encoding a ketoreductase polypeptide of claim 1 , wherein the polypeptide is capable of converting the substrate to the product at a rate that is at least 15 times greater than the rate of conversion of the substrate to the product by the reference polypeptide of SEQ ID NO: 6. 8. The polynucleotide encoding a ketoreductase polypeptide of claim 1 , wherein the polypeptide is capable of converting at least 95% of the substrate to the product in less than 24 hours when carried out with greater than 100 g/L of substrate and less than 5 g/L of the polypeptide compared to reference polypeptide of SEQ ID NO: 2. 9. An expression vector comprising the polynucleotide of claim 1 , operably linked to a control sequence suitable for directing expression in a host cell. 10. An isolated host cell comprising the expression vector of claim 9 .
Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms (C12P13/04 - C12P13/24 take precedence) · CPC title
Carbonyl reductase (NADPH) (1.1.1.184) · CPC title
Hexadecanol dehydrogenase (1.1.1.164) · CPC title
Amines; Imines · CPC title
acting on CH-OH groups as donors (1.1) · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.